N/A
Manufactured by Beiersdorf Inc
183 FDA adverse event reports analyzed
Last updated: 2026-04-15
AVOBENZONE 3%, HOMOSALATE 15%, OCTISALATE 5%, OCTOCRYLENE 10% is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Beiersdorf Inc. The most commonly reported adverse reactions for AVOBENZONE 3%, HOMOSALATE 15%, OCTISALATE 5%, OCTOCRYLENE 10% include CIRCUMSTANCE OR INFORMATION CAPABLE OF LEADING TO MEDICATION ERROR, SUNBURN, PRODUCT EXPIRATION DATE ISSUE, ACCIDENTAL EXPOSURE TO PRODUCT, EYE IRRITATION. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for AVOBENZONE 3%, HOMOSALATE 15%, OCTISALATE 5%, OCTOCRYLENE 10%.
Out of 89 classified reports for AVOBENZONE 3%, HOMOSALATE 15%, OCTISALATE 5%, OCTOCRYLENE 10%:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
This profile reflects 183 FDA FAERS reports that mention AVOBENZONE 3%, HOMOSALATE 15%, OCTISALATE 5%, OCTOCRYLENE 10%. Reporting is voluntary and does not prove that the drug caused any listed event.
Frequently reported terms in FAERS include CIRCUMSTANCE OR INFORMATION CAPABLE OF LEADING TO MEDICATION ERROR, SUNBURN, PRODUCT EXPIRATION DATE ISSUE, ACCIDENTAL EXPOSURE TO PRODUCT, EYE IRRITATION, ERYTHEMA. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.
Labeling and FAERS entries often list Beiersdorf Inc in connection with AVOBENZONE 3%, HOMOSALATE 15%, OCTISALATE 5%, OCTOCRYLENE 10%. Always verify the specific product and NDC with your pharmacist.